Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
Resources
Commentary | 2020
Safer supply, Decriminalization/legalization, Advocacy, Housing
This systematic review aims to describe and summarise psychometric properties, feasibility and clinical utility of the available tools for measuring empowerment in psychosocially vulnerable population
Lit review | 2021
Equity, Peer/PWLLE program involvement, Social benefits
Report | 2021
Overdose, Harm reduction, Policy/Regulatory, Equity, Advocacy, About prescribers, About PWUD, Legal system/law enforcement, Illegal drugs, Youth, Chronic pain, Workplace, 2SLGBTQI+, Indigenous, Sex/Gender , Mental health
Slide deck | 2019
Clinical guidance, Harm reduction, About prescribers, Illegal drugs, Hospitals
Commentary | 2021
Withdrawal, Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Stigma, Hospitals
Newsletter | 2019
Hesitancy of prescribers , Safer supply, About prescribers, Injecting drugs
Slide deck | 2021
Policy/Regulatory, Decriminalization/legalization, Advocacy, About PWUD
Commentary | 2020
Harm reduction, Policy/Regulatory, Safer supply, Decriminalization/legalization, Advocacy, About PWUD, Illegal drugs, Peer/PWLLE program involvement
The clinical guideline was developed to provide key clinical recommendations, as well as clinical guidance on the provision of iOAT.
Guidelines | 2019
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Illegal drugs, Stimulants, Transitions in care/treatment, Injecting drugs
Various practical and theoretical arguments against take-home opioid maintenance programs
Letter | 2020
Policy/Regulatory, Safer supply
To describe opioid agonist treatment prescribing rates in provincial prisons and compare with community prescribing rates.
Original research | 2021
About prescribers, Legal system/law enforcement, Substitution/OAT
Response to Tyndall
Commentary | 2019
Harm reduction, Policy/Regulatory, About prescribers, Injecting drugs
Inform PWUD about the costs and benefits of the Safe Supply options
Commentary | 2020
Policy/Regulatory, Safer supply, Advocacy, About PWUD
This manifesto builds on, and complements, the work of many other DTES organizations to empower themselves in setting up more equitable and ethical partnerships with researchers.
Report | 2019
About PWUD, Peer/PWLLE program involvement
To outline the concept of safe supply including its role in drug policy
Commentary | 2019
Harm reduction, Policy/Regulatory, Safer supply, Decriminalization/legalization, Equity, Advocacy, About PWUD, Stimulants
Scoping review to identify key concepts, strategies and gaps in evidence with respect to the provision of safe supply during pandemics and other emergencies.
Scoping review | 2020
Policy/Regulatory, Safer supply, About prescribers, About PWUD, Barriers and enablers
Commentary on Khadjesari et al 2021
Commentary | 2021
Digital health
To examine temporal trends in prescription opioid (PO) injection and to assess its association with hepatitis C virus (HCV) seroconversion among people who inject drugs (PWID).
Original research | 2019
Evidence base, Safer supply, About prescribers
This clinical trial aims to test the feasibility of a service that provides virtual overdose response in order to help prevent deaths in populations that cannot or will not access physical supervised
Other | 2021
Overdose, Harm reduction, Illegal drugs
In September 2020, xylazine was first detected by Toronto’s Drug Checking Service
Original research | 2021
Overdose, Mortality, Harm reduction, Policy/Regulatory, Decriminalization/legalization, Drug checking
